MiMedx Group (NASDAQ:MDXG) & Absci (NASDAQ:ABSI) Head to Head Analysis

MiMedx Group (NASDAQ:MDXG) and Absci (NASDAQ:ABSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Volatility and Risk

MiMedx Group has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Absci has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.

Profitability

This table compares MiMedx Group and Absci’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiMedx Group	11.60%	29.37%	21.97%
Absci	-4,113.68%	-62.33%	-53.24%

Valuation and Earnings

This table compares MiMedx Group and Absci”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63 million	1.40	$48.58 million	$0.32	12.34
Absci	$2.80 million	172.15	-$115.18 million	($0.85)	-3.71

MiMedx Group has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 1.7% of MiMedx Group shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for MiMedx Group and Absci, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	0	1	5	0	2.83
Absci	1	1	4	0	2.50

MiMedx Group presently has a consensus target price of $9.60, suggesting a potential upside of 143.04%. Absci has a consensus target price of $7.08, suggesting a potential upside of 124.76%. Given MiMedx Group’s stronger consensus rating and higher probable upside, research analysts clearly believe MiMedx Group is more favorable than Absci.

Summary

MiMedx Group beats Absci on 11 of the 14 factors compared between the two stocks.

About MiMedx Group

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.